Psychologists in Alma, MI Accepting Medicare

9 Psychologists found. Showing 1 - 9

Alesha Ruth Hall, TLLP Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 724 E Superior St, Alma, MI 48801 Phone: 989-796-4555

Mrs. Hailey Renae Cooper, MA Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 724 E Superior St, Alma, MI 48801 Phone: 989-796-4555    Fax: 989-285-1674

Norman F. Woerle, PSY.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 7820 N. Alger Road, Alma, MI 48801 Phone: 989-463-5031    Fax: 989-466-2043

Ms. Claudia Jo Unruh, MA, LLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 317 E Warwick Dr, Suite B, Alma, MI 48801 Phone: 989-463-2779    Fax: 989-463-2064

Dr. Russell Edwin Scabbo, PHD Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 317 E Warwick Dr, Suite B, Alma, MI 48801 Phone: 989-463-2779    Fax: 989-463-2064

Ms. Shelly Jean Raitz, MA Psychologist - Counseling Medicare: Medicare Enrolled Practice Location: 608 Wright Ave, Alma, MI 48801 Phone: 989-466-4127

Dr. Leslie Carol Love, PH.D. Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 110 E Superior St, Alma, MI 48801 Phone: 989-466-9200

Ms. Michelle Rae Lucchesi, MA, LLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 317 E Warwick Dr, Suite B, Alma, MI 48801 Phone: 989-463-2779    Fax: 989-463-2064

Leon Austin, PSY.D., M.S. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 116 W Superior St Ste 4, Alma, MI 48801 Phone: 989-576-0554

News Archive

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

Hepatitis B virus screening for Asian American adults can help prevent onset of liver diseases

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer.

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

In a new study by researchers in the UK, the activity of neutralizing antibodies collected from the sera of individuals that contracted COVID-19 during the first wave of the pandemic is tested against variants of concern the B.1.1.7 (or UK) variant and the B.1.351 (or South African) variant, demonstrating somewhat reduced potency of neutralization towards these strains.

FDA ODAC votes in favour of GSK's Votrient

GlaxoSmithKline announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial.

Read more Medical News

› Verified 1 days ago